Jason Rhodes is a partner and focuses on creating and building novel therapeutics companies.
Jason is the chairman and was the founding CEO of Generation Bio (NASDAQ: GBIO) and Dyne Therapeutics (NASDAQ: DYN). He is also on the boards of Replimune (NASDAQ: REPL), Gemini Therapeutics (NASDAQ: GMTX), Accent Therapeutics, Be Biopharma, K36, Rectify Pharmaceuticals, and Third Harmonic Bio. He was the chairman and founding CEO of Disarm Therapeutics, acquired by Eli Lilly in 2020.
Previously, Jason held leadership positions at Epizyme (NASDAQ: EPZM), where he was President and built the company from early stage research into the clinic and through a successful IPO in 2013, and at Alnylam Pharmaceuticals (NASDAQ: ALNY), where he led business development. Jason was also a founder and partner with Fidelity Biosciences (now F-Prime Capital), the life sciences venture capital arm of Fidelity Investments, where he led investments in therapeutics companies including FoldRx, acquired by Pfizer.
Jason received his BA from Yale University and his MBA from the Wharton School of the University of Pennsylvania.
He is a member of the advisory board of the Harvard Institute for RNA Medicine, the Blavatnik Fund at Yale University, and the Berklee College of Music Presidential Advisory Council. Jason spends his free time mountain biking and loudly watching Spanish fútbol with his family.
What is Jason P. Rhodes' net worth?
The estimated net worth of Jason P. Rhodes is at least $2.71 million as of February 28th, 2024. Ms. Rhodes owns 864,487 shares of Generation Bio stock worth more than $2,705,844 as of April 16th. This net worth evaluation does not reflect any other investments that Ms. Rhodes may own. Learn More about Jason P. Rhodes' net worth.
How do I contact Jason P. Rhodes?
Has Jason P. Rhodes been buying or selling shares of Generation Bio?
Jason P. Rhodes has not been actively trading shares of Generation Bio over the course of the past ninety days. Most recently, Jason P. Rhodes sold 16,586 shares of the business's stock in a transaction on Wednesday, September 29th. The shares were sold at an average price of $24.59, for a transaction totalling $407,849.74. Learn More on Jason P. Rhodes' trading history.
Who are Generation Bio's active insiders?
Are insiders buying or selling shares of Generation Bio?
In the last twelve months, Generation Bio insiders bought shares 2 times. They purchased a total of 12,637 shares worth more than $19,159.34. In the last twelve months, insiders at the sold shares 4 times. They sold a total of 11,591 shares worth more than $49,239.96. The most recent insider tranaction occured on January, 2nd when COO Antoinette Paone sold 2,445 shares worth more than $3,960.90. Insiders at Generation Bio own 20.8% of the company.
Learn More about insider trades at Generation Bio. Information on this page was last updated on 1/2/2024.
